Skip to main content

Bilateral anterior uveitis secondary to erlotinib

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Raymond E, Faivre S, Armand J (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(Suppl 1):15–23, discussion 41–2

    CAS  Article  PubMed  Google Scholar 

  2. NHS National Institute for Health and Clinical Excellence (2008) Lung cancer (non-small-cell)—erlotinib. http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11714. Accessed 27 June 2010

  3. Pérez-Soler R (2004) Selected highlights. Lung Cancer Frontiers 22(16):3238–3247

    Google Scholar 

  4. Thomas L, Petty MD (2003) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 1(17):3–4

    Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lik Thai Lim.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lim, L.T., Blum, R.A., Cheng, C.P. et al. Bilateral anterior uveitis secondary to erlotinib. Eur J Clin Pharmacol 66, 1277–1278 (2010). https://doi.org/10.1007/s00228-010-0873-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-010-0873-7

Keywords

  • Erlotinib
  • Anterior uveitis
  • Red eyes
  • Side effects